Home » Talecris Biotherapeutics Receives FDA Approval for Gamunex-C
Talecris Biotherapeutics Receives FDA Approval for Gamunex-C
Talecris Biotherapeutics announced Thursday that the U.S. Food and Drug Administration approved Gamunex-C for subcutaneous administration in the treatment of primary immunodeficiency.
TradingMarkets
TradingMarkets
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May